APA (7th ed.) Citation

D, Z., I, V., E, F., T, M., & D, N. (2022). Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective. The European journal of health economics : HEPAC : health economics in prevention and care, 23(8), 1371. https://doi.org/10.1007/s10198-022-01432-2

Chicago Style (17th ed.) Citation

D, Zinzi, Vlachaki I, Falla E, Mantopoulos T, and Nathwani D. "Cost-minimisation Analysis of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections from a United Kingdom Perspective." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care 23, no. 8 (2022): 1371. https://doi.org/10.1007/s10198-022-01432-2.

MLA (9th ed.) Citation

D, Zinzi, et al. "Cost-minimisation Analysis of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections from a United Kingdom Perspective." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, vol. 23, no. 8, 2022, p. 1371, https://doi.org/10.1007/s10198-022-01432-2.